AbbVie updates 2026 EPS guidance after $291M IPR&D charge
AbbVie (NYSE: ABBV) has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.91 to $14.11, following a $291 million pre-tax acquired in-process research and development (IPR&D) and milestones expense for the second quarter of 2026. This charge will reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.17. The company's second-quarter 2026 adjusted diluted EPS guidance range is now $3.57 to $3.61, incorporating the impact of this expense.
AbbVie (ABBV) Receives EU Approval for TEPKINLY in Follicular Lymphoma Treatment
AbbVie (ABBV) has received EU approval for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma. This marks the first bispecific antibody therapy authorized in Europe for second-line treatment of this condition, offering a chemotherapy-free option based on positive Phase III trial data. Despite this positive development, GuruFocus indicates that ABBV stock is currently overvalued by approximately 20.6% compared to its GF Value™, with a significantly higher P/E ratio than its historical median.
ABBV Secures EU Approval for TEPKINLY in Follicular Lymphoma Tre
AbbVie (ABBV) has received EU approval for its drug TEPKINLY in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, based on positive Phase 3 trial results. While this approval is a significant advancement for AbbVie's oncology portfolio, the company's stock shows a high P/E ratio, suggesting potential overvaluation, and its financial strength rating indicates liquidity challenges. The GF Score™ of 82 points to strong long-term potential, but investors should consider the mixed signals from valuation and insider activity.
Europe approves AbbVie’s TEPKINLY combo for relapsed follicular lymphoma
The European Commission has granted marketing authorization for AbbVie's TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R2) for adult patients with relapsed or refractory follicular lymphoma. This marks the first bispecific-based, fixed-duration, chemotherapy-free regimen approved in Europe for this setting, offering a new treatment option for a persistent form of cancer. The approval is based on Phase 3 EPCORE FL-1 trial data, which demonstrated a 79% reduction in progression or death risk, a 96% overall response rate, and a 74% complete response rate compared to R2 alone.
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
AbbVie's upcoming Q2 2026 results will likely be driven by the continued strong sales of its immunology drugs Skyrizi and Rinvoq, as the company faces the post-exclusivity decline of Humira. The article highlights AbbVie's expansion into oncology and neuroscience, while also detailing the competitive landscape with Johnson & Johnson and Eli Lilly in the immunology market. Despite a competitive environment, AbbVie's stock has outperformed the industry year-to-date and trades at a discount based on its P/E ratio.
HSBC Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $300
HSBC has reiterated its Buy rating on AbbVie (ABBV.US) and increased its price target to $300. This adjustment reflects continued confidence in the pharmaceutical company's future performance.
ABBV Maintained by Cantor Fitzgerald -- Price Target Raised to $265
Cantor Fitzgerald analyst Carter Gould maintained an "Overweight" rating on AbbVie (ABBV) and raised the price target from $240 to $265, citing a positive outlook for the company's immunology and oncology portfolio. Despite this bullish analyst view, GuruFocus indicates that ABBV is 23.2% overvalued with a GF Value of $211.93 against its current price of $261.07, and its P/E ratio of 128.61x is significantly higher than its 5-year median. Investors are advised to balance the positive analyst sentiment with the company's overvaluation according to GuruFocus metrics.
Weekly Recap: Epcoritamab Phase 3 DLBCL win and AbbVie $10M milestone to Nxera
AbbVie announced a significant Phase 3 victory for epcoritamab+lenalidomide in relapsed/refractory DLBCL, meeting the primary endpoint with strong progression-free survival hazard ratios. Concurrently, AbbVie paid Nxera a $10 million milestone, increasing 2022 neuro R&D milestones to $40 million with potential for up to $1.2 billion more. This recap highlights key developments for AbbVie regarding its drug pipeline and strategic partnerships.
The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut
The Zacks Analyst Blog features research reports on Applied Materials, Mastercard, AbbVie, INNOVATE Corp., and BranchOut Food Inc. Applied Materials is benefiting from AI-driven demand, Mastercard shows steady payment network growth despite rising costs, and AbbVie has successfully navigated Humira's loss of exclusivity with new immunology medicines. Micro-cap companies INNOVATE and BranchOut Food are highlighted for their market performance and growth opportunities, though with noted risks.
AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth
AbbVie significantly surpassed Q1 2026 revenue and adjusted EPS expectations, largely propelled by the strong performance of its immunology drugs, Skyrizi and Rinvoq. This success indicates a robust transition beyond Humira's patent cliff, leading management to raise full-year 2026 guidance. Despite some sector-wide mixed results, AbbVie's strategic pivot and pipeline advancements position it as a leader in the therapeutics industry.
5 molecular glues that could stick—and the companies stuck in
Molecular glue degraders are gaining significant traction in drug development for treating "undruggable" cancers and immunological diseases, attracting substantial funding and partnerships from major pharmaceutical companies. This article highlights five clinical programs from Bristol Myers Squibb, Monte Rosa Therapeutics, C4 Therapeutics, Neomorph, and Degron Therapeutics, showcasing their innovative approaches and the potential for these molecules to revolutionize treatment options. The use of AI in discovering novel targets is accelerating this field, creating new therapeutic avenues.
Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap
Amgen's stock is gaining momentum after a federal judge blocked Colorado's proposed 70% price cap on its key drug, Enbrel, removing a significant regulatory threat. While one fair value estimate suggests Amgen is modestly overvalued, a Discounted Cash Flow (DCF) model indicates it could be trading 45.33% below its intrinsic value. Investors are encouraged to review the valuation numbers and consider both the opportunities and risks, including potential drug pricing pressures and biosimilar competition.
Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year
The Schwab U.S. Dividend Equity ETF (SCHD) offers a quarterly distribution from approximately 100 quality U.S. dividend stocks, screening for companies with at least 10 consecutive years of dividend payments and strong financial health indicators. Six of its top holdings—AbbVie, Coca-Cola, Chevron, Lockheed Martin, Verizon, and Merck—are highlighted for their robust dividend growth and financial stability, ensuring SCHD's income stream is secure. Despite individual company challenges, their consistent performance supports the ETF's appeal for conservative investors seeking growth and income.
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
This article compares two healthcare ETFs: the Fidelity MSCI Health Care Index ETF (FHLC) and the State Street SPDR S&P Biotech ETF (XBI). FHLC offers broader diversification, lower costs, and higher dividend yield, catering to more conservative investors. XBI, focusing on the biotech subsector, provides higher recent growth but comes with increased volatility and a higher expense ratio, making it suitable for aggressive investors.
Vision Capital Management Inc. Cuts Stock Position in Johnson & Johnson $JNJ
Vision Capital Management Inc. reduced its stake in Johnson & Johnson (JNJ) by 10.1% in Q1, selling 5,703 shares and now holding 50,861 shares worth $12.4 million. Despite this, analysts maintain a "Moderate Buy" rating with a $256.70 average price target, driven by J&J's defensive appeal, recent dividend increase, and growth in its cardiac ablation and cancer pipelines. The article also highlights positive sentiment from Congressional stock purchases and new product launches, contrasting with minimal negative news.
BMY - Bristol-Myers Squibb Co Volatility & Greeks
This article provides detailed financial and performance data for Bristol-Myers Squibb Co (BMY), including its stock volatility, P/E ratios, dividend yield, and analyst recommendations. It also lists key financial metrics, insider and institutional ownership, and historical price performance over various periods.
NVS - Novartis AG ADR Volatility & Greeks
This article provides a detailed financial overview of Novartis AG ADR (NVS), including its stock performance, key financial metrics, volatility, and various ratios. It lists crucial data such as market capitalization, P/E ratio, dividend information, and insider/institutional ownership. The content also showcases recent stock price changes and performance over different periods.
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
This article reviews the Q1 2026 earnings for AbbVie and other therapeutics companies, highlighting strong performance across the sector. While AbbVie reported increased revenues and an optimistic outlook, Moderna saw the fastest revenue growth, and United Therapeutics had the weakest performance. The article also touches on shifting market narratives from AI to geopolitical risks, emphasizing the importance of fundamental strength in investments.
NVS - Novartis AG ADR Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Novartis AG ADR (NVS). It details the company's market capitalization, income, sales, dividend information, various financial ratios, and performance metrics. The report also includes insights into insider and institutional ownership, analyst recommendations, and stock performance over different periods.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak US jobs report in June, investors are shifting focus to healthcare stocks, moving away from semiconductor and AI sectors. This article highlights three healthcare companies—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that are well-positioned for resilience amidst economic uncertainties. Each company offers unique strengths, from pipeline advancements and recurring revenue models to strong market presence and dividends, making them attractive in the current investment climate.
AMGN - AMGEN Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for AMGEN Inc (AMGN). It covers various financial metrics, stock performance indicators, insider and institutional ownership details, as well as key valuation ratios and analyst recommendations. The information highlights AMGEN's recent financial health and market position.
Apogee Therapeutics stock hits all-time high at 133.32 USD
Apogee Therapeutics' stock has reached an all-time high of $133.32, with a soaring 1-year return of nearly 200%, reflecting significant investor confidence. This surge comes amid news of an acquisition by AbbVie for $135.11 per share and ongoing strategic developments like antibody discovery agreements and leadership approvals. Despite the high, some analysis suggests the stock might be overvalued based on Fair Value metrics.
Nektar Therapeutics Stock Climbs As Immunology Sentiment Improves
Nektar Therapeutics (NKTR) stock surged due to positive trial data and optimism surrounding partnerships, particularly after Canaccord cited the company as a beneficiary of AbbVie's acquisition of Apogee Therapeutics. The company is actively hiring and aligning talent with its focus on autoimmune and inflammatory diseases, led by rezpegaldesleukin which is in multiple Phase 2 trials. Despite being a clinical-stage biotech with significant R&D spend and losses, strong cash reserves and a rising stock chart are attracting momentum traders.
Should Alvotech’s Expanded US$240 Million Capital Access Require Action From Alvotech (ALVO) Investors?
Alvotech recently secured an additional US$75 million term loan, bringing its total new capital access to US$240 million, alongside a US$165 million equity raise in June 2026. This financial boost aims to fund its biosimilar pipeline and global expansion, addressing short-term liquidity concerns. However, investors are cautioned about the high-interest debt and existing leverage, especially given ongoing regulatory hurdles like the May 2026 FDA Form 483, which could impact product launch timings and milestone revenues.
AbbVie Inc Stock (ABBV) Moved Up by 3.44% on Jul 2: Drivers Behind the Movement
AbbVie Inc (ABBV) stock rose by 3.44% on July 2, driven by several key factors. Proposed changes to the 340B Drug Pricing Program are expected to benefit major drug developers like AbbVie by improving profit margins. Additionally, the company's acquisition of Apogee Therapeutics has been well-received, strengthening its immunology pipeline, and the FDA approval for Skyrizi's pediatric use significantly expands its market reach.
Biotech stocks boost ALPS Medical Breakthroughs ETF (SBIO) with 18.7% gain in June, driven by key drug trials and buyout.
The ALPS Medical Breakthroughs ETF (SBIO) saw an impressive 18.7% return in June, spurred by significant developments in biotech stocks. This surge was primarily driven by the $10.9 billion acquisition of Apogee Therapeutics by AbbVie and positive Phase 3 trial results for Definium Therapeutics' depression treatment. Oruka Therapeutics also contributed to the gains with promising psoriasis trial data, highlighting the impact of clinical success and strategic buyouts on ETF performance.
MRK - Merck & Co Inc Volatility & Greeks
This article provides comprehensive financial data for Merck & Co Inc (MRK), including its stock performance, market capitalization, income, sales, and various financial ratios. It also details dividend information, insider and institutional ownership, profitability metrics, and key analyst recommendations, offering a snapshot of the company's current financial health and market position.
Biotech Gives SBIO Its Best Month Since 2023
The ALPS Medical Breakthroughs ETF (SBIO) experienced its best single month since December 2023, returning 18.7% in June, primarily driven by biotech stock performance. Key contributors included Apogee, Definium, and Oruka, with significant surges due to drug trial results and a major acquisition. The performance highlights the importance of clinical-stage exposure for biotech investors.
West completes sale of on-body drug delivery device to AbbVie
West Pharmaceutical Services announced the completion of the sale of its SmartDose 3.5mL on-body delivery system, including manufacturing and supply rights, to AbbVie. The transaction, agreed upon in January, involved a total consideration of $112.5 million. West will continue to develop and manufacture other SmartDose versions.
AbbVie, Other Healthcare Stocks Rise as Trump Administration Reportedly Targets Hospital Drug Markups
Healthcare stocks, particularly AbbVie, experienced a rise following reports that the Trump administration is considering executive actions to reduce hospital markups on drugs. The news suggests a potential shift in drug pricing policies that could benefit some pharmaceutical companies while putting pressure on others involved in the supply chain.
AbbVie Inc. stock outperforms competitors on strong trading day
AbbVie Inc. (ABBV) stock rose by 3.99% to $261.07 on Thursday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. This gain ended a two-day losing streak for the company's shares. The rise occurred on a mixed trading day for the overall stock market.
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
This article analyzes Johnson & Johnson (J&J) and AbbVie (ABBV) to determine which offers a better investment opportunity, considering their financial strengths, pipeline developments, and challenges like patent expirations. Both companies showcase strong growth prospects, with J&J benefiting from diversification and new product launches, and AbbVie successfully navigating the Humira patent cliff with new immunology drugs. While both hold a Zacks Rank #3 (Hold), J&J is highlighted for slightly better stock performance and analyst outlook.
AstraZeneca and Abbisko collaborate on NSCLC combination therapy trial
AstraZeneca has partnered with Abbisko Therapeutics for a strategic collaboration to test the combination of Tagrisso (osimertinib) and lumipodlin (ABSK043) in patients with non-small cell lung cancer (NSCLC). This Phase I/II trial, led by Abbisko, will assess the safety and efficacy of the combination therapy for EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC, following IND approval from China's NMPA. Lumipodlin, an oral PD-L1 inhibitor developed by Abbisko, aims to block PD-1/PD-L1 interaction and enhance T-cell activation.
Regenxbio CMO Steve Pakola sells $688,755 in company stock.
Steve Pakola, Chief Medical Officer of REGENXBIO Inc. (NASDAQ:RGNX), sold $688,755 worth of company stock in recent transactions, occurring at prices between $11.04 and $12.86 per share. These sales followed an exercise of options and were conducted under a Rule 10b5-1 trading plan. The transactions take place amidst recent positive developments for Regenxbio, including progress in clinical trials for diabetic retinopathy and Duchenne muscular dystrophy, and alignment with the FDA for resubmission of an application for Mucopolysaccharidosis II treatment.
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has launched a Phase 2 clinical study for crinecerfont in pediatric patients aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). This study aims to evaluate the safety and tolerability of the drug in this young population, who currently lack approved therapies and are often exposed to high doses of glucocorticoids. The company anticipates these results will support a supplemental New Drug Application to expand Crinecerfont's approved U.S. indication to include patients under 4 years of age, building on its prior FDA approval for patients aged 4 and older.
AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment
AbbVie Inc. (ABBV) achieved a new milestone with its drug venetoclax for chronic lymphocytic leukemia (CLL) treatment, demonstrated by positive topline Phase 3 data presented at EHA 2026. The results confirm venetoclax's sustained safety and efficacy, as well as improved progression-free survival when combined with obinutuzumab. This clinical success reinforces AbbVie's commitment to delivering innovative medicines and shareholder value, as evidenced by its recent dividend declaration.
AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment
AbbVie Inc. (ABBV) announced positive topline Phase 3 data for its fixed-duration venetoclax-based combination treatment for chronic lymphocytic leukemia (CLL) at the EHA 2026 Congress. The results confirm the treatment's safety and efficacy, particularly in improving progression-free survival in untreated CLL patients. This development follows AbbVie's declaration of a $1.73-per-share quarterly dividend, demonstrating its commitment to shareholder value.
Merck & Co Inc Latest SEC Filings
This article provides a comprehensive overview of Merck & Co Inc (MRK), including its latest stock performance, key financial metrics, valuation ratios, and insider/institutional ownership data. It details the company's market capitalization, dividend information, earnings per share, sales growth, and various performance indicators over different periods. The data reflects the stock's closing price as of July 1, 2026, and offers insights for potential investors.
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
Five years ago, a $1000 investment in AbbVie (NYSE: ABBV) would now be worth $2,154.41, demonstrating an average annual return of 16.59%. This performance surpasses the market by 5.03% on an annualized basis. The article highlights the significant impact of compounded returns on investment growth over time.
H.C. Wainwright reiterates Regenxbio stock rating on trial milestone
H.C. Wainwright has reiterated a Buy rating and a $26.00 price target for Regenxbio Inc. (NASDAQ:RGNX) after the company announced a clinical trial milestone for its diabetic retinopathy treatment. Regenxbio received a $100 million payment from AbbVie for dosing the first patient in the Phase 2b/3 NAAVIGATE trial, highlighting significant progress in its gene therapy pipeline. The company also has other trials underway and plans to submit a Biologics License Application for another gene therapy in Q3 2026.
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more
This edition of Rx Rundown covers significant news in the medical marketing and pharmaceutical industry. Key highlights include Zymeworks acquiring Theravance Biopharma, several FDA approvals and rejections for new and existing drugs, and substantial funding rounds for various biotech companies. The article also notes BioCryst's decision to close its Discovery Center and cut its operating expense forecast.
Galderma Slumps After FDA Turns Down Botox Rival Relfydess
Swiss dermatology firm Galderma's shares dropped significantly after the FDA rejected its Botox rival, Relfydess. This decision marks a major setback for the company and its competitive stance against AbbVie Inc.'s Botox. The news led to Galderma's shares experiencing their largest slump in over a year.
TAK - Takeda Pharmaceutical Co ADR Options
This article provides a detailed financial overview of Takeda Pharmaceutical Co ADR (TAK) options. It includes various financial metrics such as market capitalization, income, sales, dividend information, valuation ratios, EPS estimates, and performance statistics. The data encompasses insider and institutional ownership, profitability margins, and stock performance over different periods.
REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy
REGENXBIO has dosed the first patient in its phase 2b/3 NAAVIGATE clinical trial for surabgene lomparvovec (sura-vec) for diabetic retinopathy, administering the gene therapy via suprachoroidal delivery. This investigational gene therapy, developed in collaboration with AbbVie, aims to provide sustained treatment by inhibiting VEGF, with REGENXBIO receiving a $100 million milestone payment for this first dosing. The trial will evaluate the safety and efficacy of sura-vec in patients with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME), using a 1.0x10^12 GC/eye dose and targeting a >2-step improvement on the diabetic retinopathy severity scale (DRSS) at one year.
Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial
Genmab and AbbVie have announced positive topline results from their Phase III EPCORE DLBCL-4 trial, showing that Epkinly in combination with Revlimid significantly improved progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma. This success is particularly notable following a previous negative readout for overall survival in a different trial and reinforces Epkinly's potential as a core therapy for B-cell malignancies. The data will be submitted to regulatory authorities and for presentation at a future medical meeting.
AbbVie, Genmab Blood-Cancer Drug Has Competitive Profile -- Market Talk
AbbVie and Genmab's investigational blood cancer drug, epcoritamab, has shown a competitive profile in a Phase 1/2 study, according to analysts at Jefferies. The drug, a bispecific antibody, demonstrated a 60% complete response rate in patients with large B-cell lymphoma, reinforcing its potential for a strong market position. Jefferies expects the drug to reach peak sales of $3 billion.
ABBV - Abbvie Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Abbvie Inc (ABBV). It includes key metrics such as market capitalization, income, sales, dividend information, various financial ratios, and performance indicators. The data covers areas like price performance over different periods, analyst recommendations, and insider/institutional ownership.
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A U.S. House Select Committee has launched national security investigations into five drugmakers, including Merck and AbbVie, over their involvement in clinical trials in China. The committee seeks details by July 17 regarding trials conducted in Xinjiang and military hospitals, citing concerns that these activities could aid China's military capabilities and expose American companies to ethical and security risks. This move reflects growing U.S. government concerns over China's expanding role in the biotech industry and its potential implications for national security.
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab and AbbVie's Phase 3 EPCORE DLBCL-4 trial for epcoritamab in relapsed or refractory DLBCL met its primary goal, showing significant improvement in progression-free survival. An analyst from William Blair sees potential for label expansion into second-line-plus DLBCL, representing a market of 21,000 patients, and increased confidence for a larger market opportunity in frontline DLBCL. The analyst projects up to $8 billion in revenue from related assets and rates Genmab Outperform.
AbbVie Inc. stock outperforms competitors despite losses on the day
Shares of AbbVie Inc. (ABBV) fell 1.05% on Tuesday, closing at $251.64, despite an overall positive trading session for the broader stock market. The S&P 500 Index (SPX) gained 0.79% and the Dow Jones Industrial Average (DJIA) rose 0.26%. This marks the end of a six-day winning streak for AbbVie.
